Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal

Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful, veligrotug, through clinical trials a | Viridian aims to challenge Amgen in a blockbuster market, and it's now tapped Chinese CDMO giant WuXi Biologics in a manufacturing pact.